Literature DB >> 26884109

Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.

Jolanta Krajewska1, Michał Jarząb, Agnieszka Czarniecka, Józef Roskosz, Aleksandra Kukulska, Daria Handkiewicz-Junak, Zbigniew Puch, Zbigniew Wygoda, Ewa Paliczka-Cieślik, Aleksandra Kropińska, Elżbieta Gubała, Beata Jurecka-Lubieniecka, Barbara Jarząb.   

Abstract

INTRODUCTION: Adequate postoperative risk assessment currently constitutes the principle of DTC treatment and further management. The aim of the study - a retrospective assessment of risk factors influencing DTC relapse.
MATERIAL AND METHODS: The study group consisted of 510 DTC staged pT1b-T4N0-N1M0, in whom total thyroidectomy and complementary radioiodine (RAI) treatment were carried out. In 71% papillary thyroid cancer was diagnosed, whereas in the remaining 29% - follicular thyroid carcinoma. Based on TNM classification from 1997, T1 feature was diagnosed in 11.6%, T2 in 35.1%, T3 in 8.4%, T4 in 9,4%, while in 35.5% - Tx. Lymph node metastases were present in 24.7% of cases. Median follow-up was 12.1 years (1.5-15.2).
RESULTS: Age at DTC diagnosis, tumour diameter (T), lymph node metastases (N1), stimulated thyroglobulin, and RAI uptake in thyroid bed at qualification for RAI ablation significantly influenced freedom from progression time (FFP) in a multivariate analysis. When postoperative stimulated Tg was > 30 ng/mL the risk of relapse increased nearly six-fold, whereas the presence of N1 feature - four-fold. The total risk of relapse in the whole group was 12.55% while median FFP was 154.8 months. Five-year and 10-year FFP was 90.1% and 87.5%, respectively.
CONCLUSIONS: Postoperative stimulated thyroglobulin level was the most potent, independent risk factor influencing FFP in DTC patients. Age above 60 years, an initial DTC stage (T and N features), and low RAI uptake in thyroid bed ( < 1%) were related to a higher risk of DTC relapse, whereas the investigated histopathological features were insignificant.

Entities:  

Keywords:  differentiated thyroid cancer; recurrence; risk stratification; thyroglobulin

Mesh:

Substances:

Year:  2016        PMID: 26884109     DOI: 10.5603/EP.2016.0001

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  8 in total

Review 1.  BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence.

Authors:  Agnieszka Czarniecka; Małgorzata Oczko-Wojciechowska; Marcin Barczyński
Journal:  Gland Surg       Date:  2016-10

2.  Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma.

Authors:  Jolanta Krajewska; Michal Jarzab; Aleksandra Kukulska; Agnieszka Czarniecka; Jozef Roskosz; Zbigniew Puch; Zbigniew Wygoda; Ewa Paliczka-Cieslik; Aleksandra Kropinska; Aleksandra Krol; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  Nucl Med Mol Imaging       Date:  2019-09-05

3.  The Prognostic Role of Postablative Non-Stimulated Thyroglobulin in Differentiated Thyroid Cancer.

Authors:  Szabina Szujo; Laszlo Bajnok; Beata Bodis; Zsuzsanna Nagy; Orsolya Nemes; Karoly Rucz; Emese Mezosi
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

4.  Exosomal miR-130a-3p promotes the progression of differentiated thyroid cancer by targeting insulin-like growth factor 1.

Authors:  Guang Yin; Wencheng Kong; Sixin Zheng; Yuqiang Shan; Jian Zhang; Rongchao Ying; Hao Wu
Journal:  Oncol Lett       Date:  2021-02-12       Impact factor: 2.967

5.  2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Authors:  Furio Pacini; Dagmar Fuhrer; Rossella Elisei; Daria Handkiewicz-Junak; Sophie Leboulleux; Markus Luster; Martin Schlumberger; Johannes W Smit
Journal:  Eur Thyroid J       Date:  2022-01-01

6.  Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer - a prospective comparison of long-term outcomes.

Authors:  Aleksandra Kukulska; Jolanta Krajewska; Marzena Gawkowska; Ewa Paliczka-Cieslik; Daria Handkiewicz-Junak; Aleksandra Kropińska; Zbigniew Puch; Tomasz Olczyk; Jozef Roskosz; Barbara Jarzab
Journal:  Arch Med Sci       Date:  2020-08-03       Impact factor: 3.707

7.  Stimulated Serum Thyroglobulin Levels versus Unstimulated Serum Thyroglobulin in the Follow-up of Patients with Papillary Thyroid Carcinoma.

Authors:  Saumya Sara Sunny; Julie Hephzibah; David Mathew; Joseph Dian Bondu; Nylla Shanthly; Regi Oommen
Journal:  World J Nucl Med       Date:  2018 Jan-Mar

8.  Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma.

Authors:  Tawika Kaewchur; Sirianong Namwongprom; Nipawan Waisayanand; Waralee Pongwiwattanachai; Molrudee Ekmahachai
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-04-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.